Thank you for that. And again, welcome to the Devyser. Q1 2024 Earnings Call. It's a great pleasure to have you all here. And as I said, today you will hear from me. Fredrik Alpsten, the Devyser CEO, and our chief commercial officer, Theis Kipling. I have also asked our CFO, Sabina Berlin, to join us during the Q&A session. Before we get into our Q1 numbers and talk about the positive development we are seeing. I want to take five minutes to recap what Devyser is for our new and potential new shareholders. Devyser is becoming increasingly well-known as a reliable provider of high-quality next-generation sequencing reagents. We are experiencing high growth through our innovative products and collaborations with industry giants like Thermo Fisher and Illumina. Our name and brand are gaining a lot of additional recognition. The company was founded and is driven by the value of fast and accurate diagnostics. It's the foundation for everything we do to ensure every patient has access to the correct diagnosis in the shortest possible time. Genetic tests can still require a very long time for patients before they get their results, causing worry and potential harm. Ultimately, we aim to enable faster response times for genetic tests and early detection of diseases to help people live healthier and longer lives. More than 100,000 people tested our products in Q1 2024. That is something I, and my colleagues, are very proud of. Devyser is on a journey. As you may know, we have experienced significant development over the last few years, including average organic revenue growth of 36% per year, gross margins well above 80%, the launch of many innovative products, and commercial expansions, both by setting up a direct sales organization and entering into collaborations with some of the most successful global companies. However, we are confident that we are at the beginning of a fantastic journey. Over the last 9 to 12 months, we have taken some very important steps to build a global, fast-growing, highly profitable diagnostic company. Our mission is to be the pioneering leader of diagnostic solutions providing fast, accurate, and easy-to-use solutions to labs worldwide. Our vision is a world where personalized medicine is universally available thanks to simplified and reliable genetic tests. So, what do we do? We develop and market genetic test solutions for targeted cancer therapies. We first take notice of hereditary diseases and post-transplant follow-ups. All development and manufacturing take place in-house at our facility in Stockholm. We sell our products, including probes, peptides, and software, to clinical diagnostic labs via our own sales reps. And we are partners. Or we are distributors. We aim to provide test services to labs and pharmaceutical companies. They have developed and launched more than 35 IVD and IVDR registered products. Interacting in three diagnostic areas: hereditary diseases, oncology, and post-transplantation. We're based here in Stockholm, but we have subsidiaries and sales offices in eight countries, plus a CLIA-certified laboratory in Atlanta, Georgia. We have around 120 employees. Our customers select Devyser because we provide simple, accurate and efficient genetic testing solutions. Our kits and software are easy to implement, maintain, and use for the laboratories. This has to be the foundation for all of our successful growth, because we design our products with a deep understanding of the clinical laboratory workflow and put the genetic laboratory team in focus. Recorded this in over 65 countries, the countries in blue on the map. We have four sales channels: direct sales, partners, our club, and distributors. You will hear more about that a bit later on in the presentation where Theis will cover that. Today we sell directly in some 15 countries, all in Europe and North America. We currently have one partner, Thermo Fisher Scientific, selling our transportation products exclusively in North America, Europe, Brazil, and Saudi Arabia. We have 50 plus distributors that are selling our products in some 50 countries. Our CLIA lab in Atlanta offers testing services to some of us for some of our products for the US market, and it also offers testing services to pharmaceutical and diagnostic companies. Europe is still our dominating market, with 88% of total sales for the last 12 months. America is, however, growing fast. 9% of total sales in the last 12 months, compared with 3% the year before. Africa is still a rather small area for us with only 3% of total sales. For the last 12 months, 75% of revenue came from direct sales, including the club, and 25% from distributors' sales, including the sales departments. The growth in the company is high. I would say even very high. Organic growth has been 36% on average since 2015. That despite a big hiccup in 2020 due to COVID. We reached 180 million MSEK in revenue for the last 12 months. So let's move over and talk about the third quarter. Sales developed well during the quarter and amounted to 51,006, a new record. The earlier record was from Q3 2023, when we reached 47,006. Sales growth, consisting entirely of organic growth, was 28.5% sequentially and 27.7% in local currency. Although these are high numbers, we are optimistic about increasing the growth rate even more in the future. Future growth in some of the direct markets in Europe and the distribution markets in Asia was lower than expected during the quarter. You're approved by 22%. While Asia experienced negative development, primarily due to uneven purchasing patterns from our distributors. However, we assess that Europe's modest growth is only temporary. The strong development we saw in 2023 for Europe should soon return, as several of the important steps we took in 2022 and 2023 materialize fully. You also see the negative development in Asia as temporary. During the last 12 to 18 months, we have concluded several distributor contracts in Asia, and the expectation is that these will start generating sales in the second half of 2024. Most gratifying is that the growth in North and South America continues to be strong. The first quarter showed a sales increase of 291%, although from a low level, of course, our main focus in 2024 and 2025 will be in North America and Europe. We will continue to expand and strengthen our market share in both markets. Expect continued strong growth from these regions in the future as well. Our product areas are growing strongly, particularly our transportation products. It continues to develop very well. The gross margin amount is, sorry. The gross margin jumped to 82.7%, compared with 85.2% in the same quarter last year. The lower gross margin can primarily be attributed to increased production capacity, built up to take advantage of our business opportunities and meet future expected volume increases. Significant investment has been made both in production capacity and in new employees. However, we are positive about the gross margin developments over time, partly because we have a scalable, modern manufacturing process where the increased volume will soon absorb the increased fixed costs. And partly because we still have the opportunity to increase our prices continuously. Results for the quarter were in line with our expectations. The EBIT increased to -$12.2 million, compared with -$19.1 million in the same quarter last year. As announced in the report for the third quarter of 2023. Our move to new premises has entailed some extra costs that burden the fourth quarter of 2023 and to some extent, the first quarter of 2024. Despite this, the operating expenses in the first quarter compared with the first quarter of 2023 only increased by 9.7%. We are convinced that the positive earnings development we saw in 2023 will continue and that we will reach our financial goal of an EBIT margin exceeding 20% during the period 2024 to 2026. Devyser has a very strong financial position, with 250 million MSEK in cash at the end of the quarter and no interest-bearing debts as we have moved to a new facility. We have invested quite a lot in our production capacity during the quarter. The investments in production equipment amounted to roughly 17 million MSEK during the quarter. You will not see any such investments during the rest of 2024. We will see a promising future sales development with our innovative products, high market growth, a very professional commercial organization, and some of the best commercial partners. At the moment we do not see anything that can change this. Of course, we may have single quarters that will not perform that well, but the trend is crystal clear. Sales are increasing much, and most quarters will be record quarters. High volumes will deliver high profit margins, even if we were affected in Q1 by our move to the new facility. The yellow bars show quarterly sales, and the orange line shows quarterly gross margins. With that, I will hand over to Kipling, our chief commercial officer, and he will give you a commercial outlook.